<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: This study was to evaluate the frequency and the course of the adverse effects of AZA/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> in Korean patients with <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Medical records of the patients with IBD treated with AZA/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> at Severance hospital from June 1996 to September 2006 were retrospectively analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: A total of 133 patients were studied </plain></SENT>
<SENT sid="3" pm="."><plain>Male to female ratio was 1.3:1 </plain></SENT>
<SENT sid="4" pm="."><plain>The mean age was 31.7+/-10.9 year </plain></SENT>
<SENT sid="5" pm="."><plain>Adverse effects included <z:hpo ids='HP_0001882'>leukopenia</z:hpo> occurred in 75 cases (56.4%), <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> in 32 cases (24.1%), <z:hpo ids='HP_0002829'>arthralgia</z:hpo> in 6 cases (4.5%), <z:hpo ids='HP_0012115'>hepatitis</z:hpo> in 6 cases (4.5%), <z:hpo ids='HP_0000988'>skin rash</z:hpo> in 4 cases (3.0%), <z:e sem="disease" ids="C0019360" disease_type="Disease or Syndrome" abbrv="ZONA">herpes zoster</z:e> in 3 cases (2.3%), and <z:hpo ids='HP_0002315'>headache</z:hpo> in 1 case (0.8%) </plain></SENT>
<SENT sid="6" pm="."><plain>Most of <z:e sem="disease" ids="C0023530" disease_type="Disease or Syndrome" abbrv="">leucopenia</z:e> (58.7%) developed within 3 months after maximal tolerated dose of AZA/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> and <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> frequently occurred within 3 months after start of AZA/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Thirty-eight patients (28.6%) required the discontinuation of medication due to adverse effects </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0001882'>Leukopenia</z:hpo> was the most common adverse effect of AZA/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> treatment </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0001882'>Leukopenia</z:hpo> and <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> developed frequently in the early period of treatment of AZA/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> in patients with IBD </plain></SENT>
<SENT sid="10" pm="."><plain>AZA/<z:chebi fb="1" ids="2208,50667">6-MP</z:chebi> should be used cautiously to scrutinize bone marrow suppression </plain></SENT>
</text></document>